FDA approves Botox to treat overactive bladder The U.S. Food and Drug Administration expanded the approved use of Botox to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics. Botox’s safety and effectiveness for this new indication were established in two clinical trials of 1,105 patients with symptoms of overactive bladder. Patients were randomly assigned to receive injections of 100 units of Botox or placebo. Botox is manufactured by Allergan (AGN). Reference Link
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.